Original Article
Preoperative Biliary Drainage for Cancer of the Head of the Pancreas
N Engl J Med 2010; 362:129-137January 14, 2010
- Abstract
Background
The benefits of preoperative biliary drainage, which was introduced to improve the postoperative outcome in patients with obstructive jaundice caused by a tumor of the pancreatic head, are unclear.
Methods
In this multicenter, randomized trial, we compared preoperative biliary drainage with surgery alone for patients with cancer of the pancreatic head. Patients with obstructive jaundice and a bilirubin level of 40 to 250 μmol per liter (2.3 to 14.6 mg per deciliter) were randomly assigned to undergo either preoperative biliary drainage for 4 to 6 weeks, followed by surgery, or surgery alone within 1 week after diagnosis. Preoperative biliary drainage was attempted primarily with the placement of an endoprosthesis by means of endoscopic retrograde cholangiopancreatography. The primary outcome was the rate of serious complications within 120 days after randomization.
Results
We enrolled 202 patients; 96 were assigned to undergo early surgery and 106 to undergo preoperative biliary drainage; 6 patients were excluded from the analysis. The rates of serious complications were 39% (37 patients) in the early-surgery group and 74% (75 patients) in the biliary-drainage group (relative risk in the early-surgery group, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001). Preoperative biliary drainage was successful in 96 patients (94%) after one or more attempts, with complications in 47 patients (46%). Surgery-related complications occurred in 35 patients (37%) in the early-surgery group and in 48 patients (47%) in the biliary-drainage group (relative risk, 0.79; 95% CI, 0.57 to 1.11; P=0.14). Mortality and the length of hospital stay did not differ significantly between the two groups.
Conclusions
Routine preoperative biliary drainage in patients undergoing surgery for cancer of the pancreatic head increases the rate of complications. (Current Controlled Trials number, ISRCTN31939699.)
Media in This Article
Figure 1
Enrollment and Outcomes.Figure 2
Proportion of Patients with Complications.Article Activity
- Article
Obstructive jaundice is the most common symptom in patients with periampullary cancer (located near the ampulla of Vater) or cancer of the pancreatic head. For patients with a resectable tumor who have no radiologic evidence of metastasis, surgical resection is the only option for cure.1-3 Since surgery in patients with jaundice is thought to increase the risk of postoperative complications, preoperative biliary drainage was introduced to improve the postoperative outcome.4 In several experimental studies and retrospective case series, preoperative biliary drainage reduced morbidity and mortality after surgery.4-7 However, two meta-analyses of randomized trials and a systematic review of descriptive series showed that the overall complication rate in patients undergoing preoperative biliary drainage was higher than that in patients who proceeded directly to surgery.8,9 This difference was partially explained by complications associated with the preoperative biliary drainage procedure itself. Nevertheless, preoperative biliary drainage has been incorporated into the surgical treatment of cancer of the pancreatic head in many centers.10-12 To assess the rates of serious complications and death and the length of hospital stay associated with preoperative biliary drainage, we conducted a multicenter, randomized trial comparing the preoperative procedure, followed by surgery, with surgery alone.
Methods
Study Design
We recruited patients 18 to 85 years of age who had a serum total bilirubin level of 40 to 250 μmol per liter (2.3 to 14.6 mg per deciliter) and no evidence on computed tomography (CT) of distant metastasis or local vascular involvement (which was defined as tumor surrounding portal or mesenteric vessels for more than 180 degrees of their circumference or an irregular vessel margin). The interval between CT and randomization was set to be less than 4 days. Endoscopic ultrasonography was selectively performed if the CT findings were inconclusive.
Patients with a serious coexisting illness (Karnofsky performance score, <50 [on a scale of 0 to 100, with higher scores indicating better performance]), another contraindication for major surgery, ongoing cholangitis, or previous preoperative biliary drainage with stenting by means of endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) were excluded. Other exclusion criteria were the current receipt of neoadjuvant chemotherapy or the presence of a serious gastric-outlet obstruction (tumor-related duodenal stenosis, which was defined by vomiting and an oral intake of <1 liter per day). All patients provided written informed consent.
Patients were randomly assigned to undergo either endoscopic preoperative biliary drainage for 4 to 6 weeks, followed by surgery, or surgery alone within 1 week after diagnosis. Randomization, which was stratified according to study center, was performed with a computer program at the coordinating trial center. The medical ethics committee at each study center approved the protocol, which has been described previously.13
Study Oversight
The study coordinator collected data at each study site. The trial was sponsored by the Netherlands Organization for Health Research and Development, which did not have access to outcome data during the trial and did not participate in data analyses or the preparation of the manuscript. The study coordinator, the clinical epidemiologist, and the lead academic author analyzed the data and vouch for the completeness and accuracy of the analyses. No endoscopic equipment or stents were donated by the manufacturer.
Endoscopic Preoperative Biliary Drainage
An attending gastroenterologist who was experienced in endoscopic preoperative biliary drainage performed the procedure using ERCP with plastic stent placement, with or without antibiotic prophylaxis, according to local policy. If the procedure was unsuccessful, the patient was referred to a tertiary center for a second attempt. PTC with stent placement to achieve preoperative biliary drainage was considered a rescue option in case of failed ERCP. Biliary drainage was defined as successful if the serum bilirubin level decreased by 50% or more within 2 weeks after the procedure. A new stent was placed if signs of inadequate bile drainage, with or without cholangitis, developed. After 4 to 6 weeks of drainage, patients underwent surgery.
Surgery
Five academic and eight regional hospitals agreed to provide operating-room capacity to ensure that early surgery could be performed as required by the protocol. Each of the participating hospitals performed at least 10 resections of cancer of the pancreatic head per year.
All patients received perioperative antibiotics. As prophylaxis only if indicated, patients received vitamin K for coagulation disorders and octreotide or its analogues for the treatment of a pancreas with a soft texture or a nondilated pancreatic duct. The standard surgical procedure for resectable tumors was the pylorus-preserving pancreatoduodenectomy, including removal of all lymph nodes on the right side of the portal vein and mesenteric artery.14
If metastasis into the proximal duodenum or pylorus was suspected, a classic Whipple procedure was performed, with resection of the distal stomach. If limited metastasis into the portal or superior mesenteric vein was found, a wedge resection of these vessels was included in the procedure.14,15 No specific modifications of surgical technique were expected for patients with jaundice, particularly with respect to creating the hepaticojejunostomy. The extrahepatic bile duct becomes dilated after distal obstruction, with concomitant induction of fibrosis in the duct wall, and usually remains dilated after preoperative biliary drainage because of decreased compliance of the duct. If resection was deferred because of metastasis or local spread, biopsy samples were obtained for histologic analysis. Palliative treatment generally consisted of the creation of a hepaticojejunostomy with or without gastroenterostomy and celiac plexus neurolysis.14,16,17 If a hepaticojejunostomy was not feasible, an expandable metal stent was inserted postoperatively by means of ERCP.
Evaluation of Outcomes
The primary outcome was the rate of serious complications up to 120 days after randomization, including any complication related to the drainage procedure or the surgical treatment that prompted an additional medical, endoscopic, or surgical intervention resulting in an extension of the hospital stay, readmission to the hospital, or death. The definitions and management of complications have been used in previous studies evaluating the management of complications on the basis of generally accepted criteria.18-25 (Definitions of all complications are listed in Table 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.) Secondary outcomes were mortality and the length of hospital stay. Symptoms or signs of progressive or recurrent tumor within the study period were not considered as treatment-related events.
Outpatient visits were scheduled at 2, 6, and 12 weeks after discharge. A standardized evaluation of symptoms and, if indicated, laboratory tests and radiologic studies were performed at each visit. In addition, data regarding hospital admissions and all performed procedures were collected, with special attention to any complication, including all additional endoscopic and surgical procedures. When necessary, the patient's physician was consulted for additional information.
To exclude bias in evaluating potential complications, an adjudication committee reviewed all events in a blinded fashion and classified them as serious complications or not serious, according to the definitions in the study protocol.13
Statistical Analysis
The principal analysis consisted of an intention-to-treat comparison of the proportion of patients with serious complications in the two treatment groups. The goal was to test for noninferiority of early surgery, as compared with preoperative biliary drainage, with respect to the primary outcome, and superiority with respect to secondary outcomes. Our previous meta-analysis was used to calculate the required sample size.9
Assuming that there would be a complication rate of 38% in the early-surgery group and 48% in the biliary-drainage group, we would consider early surgery to be noninferior if the associated percentage of serious complications was less than 10 percentage points above the percentage of serious complications in the biliary-drainage group. We used a two-group large-sample normal approximation test of proportions, with a one-sided significance level of 0.05, to test the null hypothesis that early surgery would lead to an increase of at least 10 percentage points in the rate of complications, as compared with preoperative biliary drainage, followed by surgery. To attain a power of 80% to show noninferiority of early surgery, 94 patients were needed in each group. We also performed a logistic-regression analysis of the complication rate with adjustment for potential prognostic factors of age, sex, body-mass index, tumor site (pancreatic vs. periampullary), and degree of jaundice. We calculated two-sided 95% confidence intervals for all outcome measures.
After the enrollment of 50% of the patients, a safety committee (consisting of a gastroenterologist, a surgeon, and a clinical epidemiologist) performed a planned, blinded interim analysis of the primary outcome, for which the nominal significance level was lowered to a more restrictive two-sided P value of less than 0.01. The committee recommended the continuation of enrollment up to the calculated sample size.
Results
Patients and Study Interventions
Between November 2003 and June 2008, a total of 202 patients underwent randomization (Figure 1Figure 1
Enrollment and Outcomes.). After randomization, two patients withdrew consent, and four patients were found to be ineligible because the serum total bilirubin level had not been in accordance with the protocol before randomization. These six patients were not included in the analyses. The demographic and clinical characteristics of the two study groups were similar at baseline, with the exception of sex and body-mass index (Table 1Table 1
Demographic and Clinical Characteristics of the Patients at Baseline.).Five patients who were assigned to the early-surgery group underwent preoperative biliary drainage for the following reasons: the surgical facility was not available in time for early surgery (in the case of three patients), intercurrent cholangitis developed after earlier ERC without preoperative biliary drainage (in one patient), and hyperglycemia (serum glucose level, 77 mmol per liter) developed (in one patient).
Of the 102 patients in the biliary-drainage group 56 (55%) underwent a first attempt at preoperative biliary drainage in a community hospital, and 46 (45%) underwent a first attempt in an academic hospital. Adequate drainage was achieved in 77 patients (75%) on the first attempt. The rates of successful initial stent placement in academic centers and community hospitals did not differ significantly (83% and 69%, respectively; P=0.13). Symptoms that were associated with obstructive jaundice resolved within 10 days after successful drainage. Reasons for initial failure of stent placement were an inability to cannulate the common bile duct in 12 patients with normal-appearing papilla, extensive tumor growth at the site of the papilla in 8 patients, and failure to reach the papilla in 1 patient with a Billroth type II gastric resection. After a second attempt, ERCP or PTC resulted in adequate drainage in 96 patients (94%). Three patients did not undergo drainage because of misdiagnosed choledocholithiasis (in two patients) and endoscopic removal of an adenomatous polyp (in one patient). There were technical failures in another three patients: failure of both ERCP and PTC (in one patient), ERCP-associated bile-duct perforation for which an emergency laparotomy with resection was performed (in one patient), and sphincterotomy-associated hemorrhage, which stopped the procedure (in one patient). The patient with hemorrhage died 18 days later as a consequence of cholangiosepsis with hemodynamic instability and preexisting cardiac failure.
The mean time to surgery was 1.2 weeks (95% confidence interval [CI], 0.9 to 1.4) for the early-surgery group and 5.2 weeks (95% CI, 4.8 to 5.5) for the biliary-drainage group. Surgical exploration was canceled in two patients in the early-surgery group because of choledocholithiasis in one patient and pulmonary metastases of a previous breast carcinoma identified during the workup in the other. Seven patients in the biliary-drainage group did not undergo surgery because of choledocholithiasis (in two patients), earlier endoscopic polyp removal (in one patient), death after preoperative biliary drainage (in the above-mentioned patient), unresectability after CT review (in two patients), and the decision (on the part of one patient) not to undergo surgical treatment after successful stent placement. The percentages of patients undergoing resection did not differ significantly between the two groups: 63 patients in the early-surgery group (67%) and 57 in the biliary-drainage group (56%) (P=0.11). The surgical techniques were similar in the two groups. Table 2 in the Supplementary Appendix lists additional procedural characteristics.
Complications
Table 2Table 2
Serious Complications within 120 Days after Randomization. lists the numbers of patients who had at least one complication related to either preoperative biliary drainage or surgery. Complications that were associated with preoperative biliary drainage occurred in 2 patients in the early-surgery group (2%) and in 47 patients in the biliary-drainage group (46%). Of the 27 patients in whom cholangitis developed (with or without stent occlusion), 3 patients had two episodes. The mean interval from randomization to the first complication related to preoperative biliary drainage in the biliary-drainage group was 13 days (95% CI, 10 to 16). Surgery-related complications occurred in 35 patients in the early-surgery group (37%) and in 48 patients in the biliary-drainage group (47%), for a relative risk of 0.79 (95% CI, 0.57 to 1.11) in the early-surgery group. There was no significant difference in surgical outcome between academic and community hospitals (P=0.21).Figure 2Figure 2
Proportion of Patients with Complications. shows the cumulative proportion of patients in each group with one or more complications. The rates of serious complications were 39% (37 patients) in the early-surgery group and 74% (75 patients) in the biliary-drainage group; the relative risk of serious complications with early surgery was 0.54 (95% CI, 0.41 to 0.71) (Table 3Table 3
Major Outcomes.). We rejected the null hypothesis of an increase in complications in the early-surgery group (P<0.001 by a one-sided normal-approximation test). An additional test of superiority showed that early surgery led to fewer complications than preoperative biliary drainage (P<0.001). The difference was also significant in the logistic-regression analysis (P<0.001).Patients in the biliary-drainage group, as compared with those in the early-surgery group, had significantly more readmissions for complications and stayed on average 2 days longer in the hospital. There was no significant difference in mortality between the groups. Among patients who underwent a palliative bypass procedure, surgical complications developed in 18 of 33 patients (55%) in the biliary-drainage group, as compared with 5 of 28 patients (18%) in the early-surgery group (P=0.003).
Discussion
In this multicenter, randomized trial, we examined whether preoperative biliary drainage should be performed routinely in patients with obstructive jaundice caused by cancer of the pancreatic head before resection. We found that endoscopic preoperative biliary drainage with placement of a plastic stent did not have a beneficial effect on the surgical outcome. Early surgery without preoperative biliary drainage did not increase the risk of complications, as compared with preoperative biliary drainage, followed by surgery.
The postoperative complication rate did not differ significantly between the two groups, as has been reported previously.26-29 With respect to complications related to endoscopic preoperative biliary drainage, the incidence of pancreatitis, perforation, or hemorrhage in our study was in accordance with the incidence reported by others.30-32 The rate of cholangitis associated with preoperative biliary drainage was high and an important reason for readmission. This high incidence of cholangitis was reported within the same range by all participating centers.
In contrast with earlier randomized studies, our study showed that preoperative biliary drainage did not necessarily prolong the length of the hospital stay. The previously observed extended hospital stay can be attributed to the use of PTC drainage, whereas endoscopic drainage, as used in our study, is often performed on an outpatient basis. The use of preoperative biliary drainage did not influence postoperative mortality. Pancreatic surgery that is performed in high-volume centers is associated with death rates that are well below 5%, an important argument for centralization of such complex surgical procedures.26,33 In our study, the overall rate of death was 7% (which included one patient who died after the biliary-drainage procedure) and did not differ significantly between the two treatment strategies.
The optimal duration of biliary drainage before surgery has not been established. Experimental and clinical studies have suggested that a period of at least 4 to 6 weeks is needed for the restoration of normal major synthetic and clearance functions of the liver, as well as mucosal intestinal barrier functions.4 A short period of drainage may not lead to full recovery of the metabolic abnormalities associated with obstructive jaundice. In four randomized studies that did not show a benefit of preoperative biliary drainage, the mean duration of drainage was 7 to 18 days.8 Our trial called for 4 to 6 weeks of drainage. An even longer period would be unlikely to yield better results, would increase the risk of stent occlusion and inflammation of the bile-duct wall,9 and would result in a prolonged postponement of surgery that would be unjustifiable for a potentially resectable tumor.
Beneficial effects of preoperative biliary drainage were found in early, nonrandomized studies that involved a small number of patients and an imperfect methodologic design. In four of five randomized trials, preoperative biliary drainage by means of PTC was the standard mode of drainage, whereas ERCP, a less invasive procedure, is currently preferred.11 The consequences of percutaneous and endoscopic drainage differ largely in terms of restoration of the enterohepatic cycle and bacterial colonization and inflammation of the biliary tract.4,7 The percutaneous route is reserved for failed endoscopic attempts. In these studies, tumors causing proximal and distal bile-duct obstruction were included, but such tumors are now considered to be different diseases and to require different forms of treatment.
With the advent of neoadjuvant chemotherapy used to downstage potentially unresectable tumors in the hope of improving the outcome, the issue of preoperative biliary drainage is clinically relevant.34-36 In light of our poor results with plastic stents, preoperative biliary drainage during the period of neoadjuvant treatment might be best achieved with metal stents, which have a higher patency rate than plastic stents and do not affect the outcome of surgery.37-39
Supported by the Netherlands Organization for Health Research and Development.
Dr. Bruno reports receiving lecture fees from Boston Scientific; and Dr. Greve, consulting fees from GI Dynamics and lecture fees from Covidien and Johnson & Johnson. No other potential conflict of interest relevant to this article was reported.
We thank Huug Obertop (formerly of the Academic Medical Center in Amsterdam and more recently of the Erasmus Medical Center in Rotterdam); Paul Fockens, Sapphire Phoa, and Otto van Delden of the Academic Medical Center in Amsterdam; Ernst Kuipers of the Erasmus Medical Center in Rotterdam; and the patients and their families for their contributions to the study.
Source Information
From the Departments of Surgery (N.A.G., S.M.M.C., O.R.C.B., T.M.G, D.J.G.), Gastroenterology (E.A.J.R.), Radiology (C.Y.N.), and Clinical Epidemiology and Biostatistics (P.M.M.B.), Academic Medical Center, Amsterdam; the Departments of Surgery (C.H.J.E.) and Gastroenterology (M.J.B.), Erasmus Medical Center, Rotterdam; the Departments of Surgery (E.H.) and Gastroenterology (F.J.G.M.K.), Maasstad Hospital, Rotterdam; the Department of Surgery, Medical Spectrum Twente, Enschede (J.J.G.M.G.); the Department of Surgery, University Hospital Maastricht, Maastricht (J.W.G.); the Department of Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam (M.F.G.); the Department of Surgery, Catharina Hospital, Eindhoven (I.H.J.T.H.); and the Department of Surgery, Rijnstaete Hospital, Arnhem (J.H.K.) — all in the Netherlands.
Address reprint requests to Dr. Gouma at the Department of Surgery, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands, or at d.j.gouma@amc.uva.nl.
Additional contributors to the study are listed in the Appendix.
Appendix
In addition to the authors, the following investigators participated in this study (all institutions are in the Netherlands): Academic Medical Center, Amsterdam — P.R. de Reuver; Erasmus Medical Center, Rotterdam — M.J. Morak, C. Pek, J. van der Zee; Maasstad Hospital, Rotterdam — P.P. Coene; Medisch Spectrum Twente, Enschede — J. Klaasse, M. Russell; Academic Hospital, Maastricht — R. van Dam, J.P. Rutten, C.H. Dejong; Onze Lieve Vrouwe Gasthuis, Amsterdam — L.T. de Wit, A.E. Geraedts; Catharina Hospital, Eindhoven — S. Nienhuis; Rijnstaete Hospital, Arnhem — M. Spanier; Antonius Hospital, Nieuwegein — D. Boerma, B. van Ramshorst, R. Timmer; University Hospital, Utrecht — M.G. Besselink, H.J. van Santvoort, H.G. Gooszen, P.D. Siersema; Elisabeth Hospital, Tilburg — J. Heisterkamp, C.J. van Laarhoven; Gelre Hospitals, Apeldoorn — E.J. Hesselink; Atrium Medical Center, Heerlen — M. Sosef, P. van der Schaar; Leiden University Medical Center — B. Bonsing, P. Doornebosch. Protocol Committee — C.H.J. van Eijck, M.J. Bruno, E.A. Rauws, S.M.M. de Castro, O.R. Busch, T.M. van Gulik, P.M.M. Bossuyt, D.J. Gouma; Adjudication Committee — E.A. Rauws, T.M. van Gulik, D.J. Gouma; Steering Committee — N.A. van der Gaag, T.M. van Gulik, P. Fockens, P.M.M. Bossuyt, D.J. Gouma; Statistical Analysis — N.A. van der Gaag, S.M.M. de Castro, D.J. Gouma, P.M.M. Bossuyt; Manuscript Preparation — N.A. van der Gaag, E.A. Rauws, C.H.J. van Eijck, M.J. Bruno, O.R. Busch, T.M. van Gulik, P.M.M. Bossuyt, D.J. Gouma; Data Collection — N.A. van der Gaag, S.M.M. de Castro.
- References
References
1
Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 2005;54:Suppl 5:v1-v16
Medline2
de Groen PC ,Gores GJ ,LaRusso NF ,Gunderson LL ,Nagorney DM . Biliary tract cancers. N Engl J Med 1999;341:1368-1378
Full Text | Web of Science | Medline3
Phoa SS ,Reeders JW ,Rauws EA ,De Wit L ,Gouma DJ ,Lameris JS . Spiral computed tomography for preoperative staging of potentially resectable carcinoma of the pancreatic head. Br J Surg 1999;86:789-794
CrossRef | Web of Science | Medline4
van der Gaag NA ,Kloek JJ ,de Castro SM ,Busch OR ,van Gulik TM ,Gouma DJ . Preoperative biliary drainage in patients with obstructive jaundice: history and current status. J Gastrointest Surg 2009;13:814-820
CrossRef | Web of Science | Medline5
Klinkenbijl JH ,Jeekel J ,Schmitz PI , et al. Carcinoma of the pancreas and periampullary region: palliation versus cure. Br J Surg 1993;80:1575-1578
CrossRef | Web of Science | Medline6
Trede M ,Schwall G . The complications of pancreatectomy. Ann Surg 1988;207:39-47
CrossRef | Web of Science | Medline7
Kimmings AN ,van Deventer SJ ,Obertop H ,Rauws EA ,Huibregtse K ,Gouma DJ . Endotoxin, cytokines, and endotoxin binding proteins in obstructive jaundice and after preoperative biliary drainage. Gut 2000;46:725-731
CrossRef | Web of Science | Medline8
Wang Q ,Gurusamy KS ,Lin H ,Xie X ,Wang C . Preoperative biliary drainage for obstructive jaundice. Cochrane Database Syst Rev 2008;3:CD005444-CD005444
Medline9
Sewnath ME ,Karsten TM ,Prins MH ,Rauws EJ ,Obertop H ,Gouma DJ . A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg 2002;236:17-27
CrossRef | Web of Science | Medline10
Lillemoe KD . Preoperative biliary drainage and surgical outcome. Ann Surg 1999;230:143-144
CrossRef | Web of Science | Medline11
Sewnath ME ,Birjmohun RS ,Rauws EA ,Huibregtse K ,Obertop H ,Gouma DJ . The effect of preoperative biliary drainage on postoperative complications after pancreaticoduodenectomy. J Am Coll Surg 2001;192:726-734
CrossRef | Web of Science | Medline12
Pisters PW ,Hudec WA ,Hess KR , et al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg 2001;234:47-55
CrossRef | Web of Science | Medline13
van der Gaag NA ,de Castro SM ,Rauws EA , et al. Preoperative biliary drainage for periampullary tumors causing obstructive jaundice: DRainage vs. (direct) OPeration (DROP-trial). BMC Surg 2007;7:3-3
CrossRef | Medline14
Gouma DJ ,Nieveen van Dijkum EJ ,Obertop H . The standard diagnostic work-up and surgical treatment of pancreatic head tumours. Eur J Surg Oncol 1999;25:113-123
CrossRef | Web of Science | Medline15
van Geenen RC ,Ten Kate FJ ,de Wit LT ,van Gulik TM ,Obertop H ,Gouma DJ . Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy. Surgery 2001;129:158-163
CrossRef | Web of Science | Medline16
van Heek NT ,de Castro SM ,van Eijck CH , et al. The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg 2003;238:894-902
CrossRef | Web of Science | Medline17
Lillemoe KD ,Cameron JL ,Kaufman HS ,Yeo CJ ,Pitt HA ,Sauter PK . Chemical splanchnicectomy in patients with unresectable pancreatic cancer: a prospective randomized trial. Ann Surg 1993;217:447-455
CrossRef | Web of Science | Medline18
Gouma DJ ,van Geenen RC ,van Gulik TM , et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000;232:786-795
CrossRef | Web of Science | Medline19
Karsten TM ,Allema JH ,Reinders M , et al. Preoperative biliary drainage, colonisation of bile and postoperative complications in patients with tumours of the pancreatic head: a retrospective analysis of 241 consecutive patients. Eur J Surg 1996;162:881-888
Medline20
van Berge Henegouwen MI ,van Gulik TM ,Akkermans LM ,Jansen JB ,Gouma DJ . The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers. Gut 1997;41:758-762
CrossRef | Web of Science | Medline21
Huibregtse K . Complications of endoscopic sphincterotomy and their prevention. N Engl J Med 1996;335:961-963
Full Text | Web of Science | Medline22
Cotton PB ,Lehman G ,Vennes J , et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383-393
CrossRef | Web of Science | Medline23
de Castro SM ,Busch OR ,van Gulik TM ,Obertop H ,Gouma DJ . Incidence and management of pancreatic leakage after pancreatoduodenectomy. Br J Surg 2005;92:1117-1123
CrossRef | Web of Science | Medline24
de Castro SM ,Kuhlmann KF ,Busch OR , et al. Delayed massive hemorrhage after pancreatic and biliary surgery: embolization or surgery? Ann Surg 2005;241:85-91
Web of Science | Medline25
de Castro SM ,Kuhlmann KF ,Busch OR , et al. Incidence and management of biliary leakage after hepaticojejunostomy. J Gastrointest Surg 2005;9:1163-1171
CrossRef | Web of Science | Medline26
Cameron JL ,Riall TS ,Coleman J ,Belcher KA . One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244:10-15
CrossRef | Web of Science | Medline27
Diener MK ,Knaebel HP ,Heukaufer C ,Antes G ,Buchler MW ,Seiler CM . A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma. Ann Surg 2007;245:187-200
CrossRef | Web of Science | Medline28
Schnelldorfer T ,Ware AL ,Sarr MG , et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 2008;247:456-462
CrossRef | Web of Science | Medline29
Balcom JH IV ,Rattner DW ,Warshaw AL ,Chang Y ,Fernandez-del Castillo C . Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001;136:391-398
CrossRef | Web of Science | Medline30
Freeman ML . Understanding risk factors and avoiding complications with endoscopic retrograde cholangiopancreatography. Curr Gastroenterol Rep 2003;5:145-153
CrossRef | Medline31
Christensen M ,Matzen P ,Schulze S ,Rosenberg J . Complications of ERCP: a prospective study. Gastrointest Endosc 2004;60:721-731
CrossRef | Web of Science | Medline32
Williams EJ ,Taylor S ,Fairclough P , et al. Risk factors for complication following ERCP: results of a large-scale, prospective multicenter study. Endoscopy 2007;39:793-801
CrossRef | Web of Science | Medline33
Birkmeyer JD ,Stukel TA ,Siewers AE ,Goodney PP ,Wennberg DE ,Lucas FL . Surgeon volume and operative mortality in the United States. N Engl J Med 2003;349:2117-2127
Full Text | Web of Science | Medline34
Katz MH ,Pisters PW ,Evans DB , et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206:833-846
CrossRef | Web of Science | Medline35
Evans DB ,Varadhachary GR ,Crane CH , et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3496-3502
CrossRef | Web of Science | Medline36
Varadhachary GR ,Wolff RA ,Crane CH , et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3487-3495
CrossRef | Web of Science | Medline37
Davids PH ,Groen AK ,Rauws EA ,Tytgat GN ,Huibregtse K . Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992;340:1488-1492
CrossRef | Web of Science | Medline38
Moss AC ,Morris E ,Leyden J ,MacMathuna P . Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev 2007;33:213-221
CrossRef | Web of Science | Medline39
Mullen JT ,Lee JH ,Gomez HF , et al. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg 2005;9:1094-1104
CrossRef | Web of Science | Medline
- Citing Articles (48)
Citing Articles
1
Divyesh Sejpal. (2012) Advancements in Biliary Stenting. Journal of Clinical Gastroenterology 46:3, 191-196
CrossRef2
Sathya Jaganmohan, Jeffrey H Lee. (2012) Self-expandable metal stents in malignant biliary obstruction. Expert Review of Gastroenterology & Hepatology 6:1, 105-114
CrossRef3
D. Hoem, A. Viste. (2012) Improving survival following surgery for pancreatic ductal adenocarcinoma – A ten-year experience. European Journal of Surgical Oncology (EJSO)
CrossRef4
Jacqueline G. O’Leary, Lawrence S. Friedman. 2012. Surgery in the patient with liver disease and postoperative jaundice. , 403-419.
CrossRef5
Hai-Dong Zhu, Jin-He Guo, Guang-Yu Zhu, Shi-Cheng He, Wen Fang, Gang Deng, Yong-Lin Qin, Guo-Zhao Li, Douglas M. Coldwell, Gao-Jun Teng. (2012) A novel biliary stent loaded with 125I seeds in patients with malignant biliary obstruction: preliminary results versus a conventional biliary stent. Journal of Hepatology
CrossRef6
Kunal Jajoo, Kevin Mennitt, Ira Jacobson. 2011. Noninvasive and Invasive Imaging of the Liver and Biliary Tract. , 58-86.
CrossRef7
Lawrence S. Friedman. 2011. Preoperative Evaluation of the Patient with Liver Disease. , 316-325.
CrossRef8
Ashwani K. Singal, William A. Ross, Praveen Guturu, Gauri R. Varadhachary, Milind Javle, Sathya R. Jaganmohan, Ramu P. Raju, Jason B. Fleming, Gottumukala S. Raju, Yong-Fang Kuo, Jeffrey H. Lee. (2011) Self-Expanding Metal Stents for Biliary Drainage in Patients with Resectable Pancreatic Cancer: Single-Center Experience with 79 Cases. Digestive Diseases and Sciences 56:12, 3678-3684
CrossRef9
J. R. A. Skipworth, S. W. M. Olde Damink, C. Imber, J. Bridgewater, S. P. Pereira, M. Malagó. (2011) Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. Alimentary Pharmacology & Therapeutics 34:9, 1063-1078
CrossRef10
B. Malgras, C. Pierret, J.-P. Tourtier, G. Olagui, C. Nizou, V. Duverger. (2011) Double perforation sigmoïdienne par migration d’une endoprothèse biliaire. Journal de Chirurgie Viscérale 148:5, 449-451
CrossRef11
B. Malgras, C. Pierret, J.-P. Tourtier, G. Olagui, C. Nizou, V. Duverger. (2011) Double Sigmoid colon perforation due to migration of a biliary stent. Journal of Visceral Surgery 148:5, e397-e399
CrossRef12
Gregory A. Coté, Stuart Sherman. (2011) Biliary Stricture and Negative Cytology: What Next?. Clinical Gastroenterology and Hepatology 9:9, 739-743
CrossRef13
Haiyang Zhou, Jian Zhang, Weijun Wang, Zhiqian Hu. (2011) Does Preoperative Biliary Drainage Associated Time Delay Harm? From Trial Design to Conclusion. Annals of Surgery 254:3, 542-543
CrossRef14
Eduardo A. Bonin, Todd H. Baron. (2011) Preoperative biliary stents in pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences 18:5, 621-629
CrossRef15
Wietse J. Eshuis, Niels A. van der Gaag, Dirk J. Gouma. (2011) Does Preoperative Biliary Drainage Associated Time Delay Harm? From Trial Design to Conclusion. Annals of Surgery 254:3, 543
CrossRef16
Tomohisa Okaya, Koji Nakagawa, Fumio Kimura, Hiroaki Shimizu, Hiroyuki Yoshidome, Masayuki Ohtsuka, Atsushi Kato, Hideyuki Yoshitomi, Hiroshi Ito, Masaru Miyazaki. (2011) The alterations in hepatic microcirculation and Kupffer cell activity after biliary drainage in jaundiced mice. Journal of Hepato-Biliary-Pancreatic Sciences
CrossRef17
Audrey Vincent, Joseph Herman, Rich Schulick, Ralph H Hruban, Michael Goggins. (2011) Pancreatic cancer. The Lancet 378:9791, 607-620
CrossRef18
Jeffrey H. Lee. (2011) Self-Expandable Metal Stents for Malignant Distal Biliary Strictures. Gastrointestinal Endoscopy Clinics of North America 21:3, 463-480
CrossRef19
Tarek M. Ezzat, Dipok K. Dhar, Philip N. Newsome, Massimo Malagó, Steven W. M. Olde Damink. (2011) Use of hepatocyte and stem cells for treatment of post-resectional liver failure: are we there yet?. Liver International 31:6, 773-784
CrossRef20
Inge Huibregtse, Paul Fockens. (2011) Plastic Biliary Stents for Malignant Biliary Diseases. Gastrointestinal Endoscopy Clinics of North America 21:3, 435-445
CrossRef21
Christopher Decker, John D. Christein, Milind A. Phadnis, C. Mel Wilcox, Shyam Varadarajulu. (2011) Biliary metal stents are superior to plastic stents for preoperative biliary decompression in pancreatic cancer. Surgical Endoscopy 25:7, 2364-2367
CrossRef22
Rahul S. Koti, Brian R. Davidson. 2011. Malignant Biliary Diseases. , 294-311.
CrossRef23
Louis M Wong Kee Song, Todd H Baron. (2011) Stenting for acute malignant colonic obstruction: a bridge to nowhere?. The Lancet Oncology 12:4, 314-315
CrossRef24
George H. Pop, James A. Richter, Bryan Sauer, Michele E. Rehan, Henry C. Ho, Reid B. Adams, Todd Bauer, Vanessa M. Shami, Melissa S. Phillips, Michel Kahaleh. (2011) Bridge to surgery using partially covered self-expandable metal stents (PCMS) in malignant biliary stricture: an acceptable paradigm?. Surgical Endoscopy 25:2, 613-618
CrossRef25
Mirja Sargent, Stefan Boeck, Volker Heinemann, Karl-Walter Jauch, Thomas Seufferlein, Christiane J. Bruns. (2011) Surgical treatment concepts for patients with pancreatic cancer in Germany—results from a national survey conducted among members of the “Chirurgische Arbeitsgemeinschaft Onkologie” (CAO) and the “Arbeitsgemeinschaft Internistische Onkologie” (AIO) of the Germany Cancer Society (DKG). Langenbeck's Archives of Surgery 396:2, 223-229
CrossRef26
T.M. van Gulik, J.J. Kloek, A.T. Ruys, O.R.C. Busch, G.J. van Tienhoven, J.S. Lameris, E.A.J. Rauws, D.J. Gouma. (2011) Multidisciplinary management of hilar cholangiocarcinoma (Klatskin tumor): Extended resection is associated with improved survival. European Journal of Surgical Oncology (EJSO) 37:1, 65-71
CrossRef27
Eva B. Deerenberg, Jan-Werner Poley, John J. Hermans, Sjam Ganesh, Erwin van der Harst, Casper H.J. van Eijck. (2011) Role of Endoscopic Ultrasonography in Patients Suspected of Pancreatic Cancer with Negative Helical MDCT Scan. Digestive Surgery 28:5-6, 398-403
CrossRef28
Gareth Morris-Stiff, Appou Tamijmarane, Yu-Meng Tan, Iestyn Shapey, Chandra Bhati, A. David Mayer, John A.C. Buckels, Simon R. Bramhall, Darius F. Mirza. (2011) Pre-operative stenting is associated with a higher prevalence of post-operative complications following pancreatoduodenectomy. International Journal of Surgery 9:2, 145-149
CrossRef29
Phillipo L Chalya, Emmanuel S Kanumba, Mabula Mchembe. (2011) Etiological spectrum and treatment outcome of Obstructive jaundice at a University teaching Hospital in northwestern Tanzania: A diagnostic and therapeutic challenges. BMC Research Notes 4:1, 147
CrossRef30
Thomas M. van Gulik, Anthony T. Ruys, Oliver R.C. Busch, Erik A.J. Rauws, Dirk J. Gouma. (2011) Extent of Liver Resection for Hilar Cholangiocarcinoma (Klatskin Tumor): How Much Is Enough?. Digestive Surgery 28:2, 141-147
CrossRef31
M.T. Huggett, P. Ghaneh, S.P. Pereira. (2010) Drainage and Bypass Procedures for Palliation of Malignant Diseases of the Upper Gastrointestinal Tract. Clinical Oncology 22:9, 755-763
CrossRef32
John P. Neoptolemos, Martin Lombard, Christopher M. Halloran. (2010) Authors' reply: PBD treatment of cancer of the head of the pancreas. Nature Reviews Clinical Oncology 7:11,
CrossRef33
Niels A. van der Gaag, Dirk J. Gouma. (2010) PBD treatment of cancer of the head of the pancreas. Nature Reviews Clinical Oncology 7:11,
CrossRef34
Wietse J. Eshuis, Niels A. van der Gaag, Erik A.J. Rauws, Casper H.J. van Eijck, Marco J. Bruno, Ernst J. Kuipers, Peter P. Coene, Frank J.G.M. Kubben, Josephus J.G.M. Gerritsen, Jan Willem Greve, Michael F. Gerhards, Ignace H.J.T. de Hingh, Jean H. Klinkenbijl, C.Y. Nio, Steve M.M. de Castro, Olivier R.C. Busch, Thomas M. van Gulik, Patrick M.M. Bossuyt, Dirk J. Gouma. (2010) Therapeutic Delay and Survival After Surgery for Cancer of the Pancreatic Head With or Without Preoperative Biliary Drainage. Annals of Surgery 252:5, 840-849
CrossRef35
J. Boitard, A. Laquière. (2010) Les prothèses digestives. Acta Endoscopica 40:5, 367-372
CrossRef36
Vedra A. Augenstein, Nathan P. Reuter, Matthew R. Bower, Kelly M. McMasters, Charles R. Scoggins, Robert C.G. Martin. (2010) Bile cultures: A guide to infectious complications after pancreaticoduodenectomy. Journal of Surgical Oncology 102:5, 478-481
CrossRef37
Muslim Atiq, Milind Javle, Shyam Dang, Jeffrey H Lee. (2010) Cholangiocarcinoma: an endoscopist’s perspective. Expert Review of Gastroenterology & Hepatology 4:5, 601-611
CrossRef38
Gregory A Coté, Stuart Sherman. (2010) Advances in pancreatobiliary endoscopy. Current Opinion in Gastroenterology 26:5, 429-435
CrossRef39
(2010) Scientific Surgery. British Journal of Surgery 97:8, 1313-1313
CrossRef40
Jason N. Rogart. (2010) The Plastic Biliary Stent. Journal of Clinical Gastroenterology 44:6, 389-390
CrossRef41
(2010) Journal Club. Medizinische Klinik 105:6, 439-449
CrossRef42
Jürgen F. Riemann, Axel Eickhoff. (2010) Pancreas: Preoperative biliary drainage for pancreatic cancer. Nature Reviews Gastroenterology & Hepatology 7:6, 308-309
CrossRef43
Daniel J. Renouf, Malcolm J. Moore. (2010) Surgical oncology: Is PBD suitable for resectable pancreatic cancer?. Nature Reviews Clinical Oncology 7:5, 246-247
CrossRef44
John P. Neoptolemos, Christopher M. Halloran. (2010) Surgical oncology: PBD—better stents in specialized centers are needed. Nature Reviews Clinical Oncology 7:5, 244-246
CrossRef45
(2010) Preoperative Drainage in Pancreatic Cancer. New England Journal of Medicine 362:14, 1342-1346
Full Text46
Jaap J. Kloek, Michal Heger, Niels A. van der Gaag, Ulrich Beuers, Thomas M. van Gulik, Dirk J. Gouma, Marcel Levi. (2010) Effect of Preoperative Biliary Drainage on Coagulation and Fibrinolysis in Severe Obstructive Cholestasis. Journal of Clinical Gastroenterology1
CrossRef47
Baron, Todd H., Kozarek, Richard A., . (2010) Preoperative Biliary Stents in Pancreatic Cancer — Proceed with Caution. New England Journal of Medicine 362:2, 170-172
Full Text48
Richard A. Kozarek. (2010) The Society for Gastrointestinal Intervention. Are We, as an Organization of Disparate Disciplines, Cooperative or Competitive?. Gut and Liver 4:Suppl. 1, S1
CrossRef
- Letters
